These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 3295044

  • 1. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.
    Palladino MA, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, Crase D, Marafino B, Aggarwal BB, Figari IS.
    J Immunol; 1987 Jun 01; 138(11):4023-32. PubMed ID: 3295044
    [Abstract] [Full Text] [Related]

  • 2. Effects of growth factors on the antiproliferative activity of tumor necrosis factors.
    Sugarman BJ, Lewis GD, Eessalu TE, Aggarwal BB, Shepard HM.
    Cancer Res; 1987 Feb 01; 47(3):780-6. PubMed ID: 3802082
    [Abstract] [Full Text] [Related]

  • 3. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
    Manda T, Shimomura K, Mukumoto S, Kobayashi K, Mizota T, Hirai O, Matsumoto S, Oku T, Nishigaki F, Mori J.
    Cancer Res; 1987 Jul 15; 47(14):3707-11. PubMed ID: 3594435
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy, or immunotherapy.
    Haranaka K, Sakurai A, Satomi N.
    J Biol Response Mod; 1987 Aug 15; 6(4):379-91. PubMed ID: 3625230
    [Abstract] [Full Text] [Related]

  • 5. Effects of monoclonal antibody, recombinant interferon-gamma, and tumor necrosis factor-alpha in the treatment of human melanoma xenografts.
    Gridley DS, Slater JM, Stickney DR.
    J Biol Response Mod; 1989 Dec 15; 8(6):593-602. PubMed ID: 2513378
    [Abstract] [Full Text] [Related]

  • 6. Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha.
    Kramer SM, Aggarwal BB, Eessalu TE, McCabe SM, Ferraiolo BL, Figari IS, Palladino MA.
    Cancer Res; 1988 Feb 15; 48(4):920-5. PubMed ID: 2827889
    [Abstract] [Full Text] [Related]

  • 7. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
    Alleva DG, Burger CJ, Elgert KD.
    J Immunol; 1994 Aug 15; 153(4):1674-86. PubMed ID: 8046239
    [Abstract] [Full Text] [Related]

  • 8. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
    Nanjo M, Yoshie O, Aso H, Ebina T, Ishida N.
    Gan To Kagaku Ryoho; 1985 Mar 15; 12(3 Pt 1):505-9. PubMed ID: 4004283
    [Abstract] [Full Text] [Related]

  • 9. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R, Malloy B, Sherrod A, Bean P, Girgis E, Mazumder A.
    J Biol Response Mod; 1988 Apr 15; 7(2):140-51. PubMed ID: 3258905
    [Abstract] [Full Text] [Related]

  • 10. Therapy combining tumor necrosis factor with tumor-specific antibody against Meth A sarcoma.
    Satomi N, Sakurai A, Haranaka R, Haranaka K.
    J Biol Response Mod; 1989 Oct 15; 8(5):528-38. PubMed ID: 2677250
    [Abstract] [Full Text] [Related]

  • 11. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
    Tsutsumi Y, Kihira T, Tsunoda S, Kamada H, Nakagawa S, Kaneda Y, Kanamori T, Mayumi T.
    J Pharmacol Exp Ther; 1996 Sep 15; 278(3):1006-11. PubMed ID: 8819479
    [Abstract] [Full Text] [Related]

  • 12. Modulation of the growth of transformed cells by human tumor necrosis factor-alpha and interferon-gamma.
    Lewis GD, Aggarwal BB, Eessalu TE, Sugarman BJ, Shepard HM.
    Cancer Res; 1987 Oct 15; 47(20):5382-5. PubMed ID: 2820567
    [Abstract] [Full Text] [Related]

  • 13. [Antitumor activity of tumor necrosis factor (TNF) in vitro and in vivo].
    Haranaka K, Satomi N, Sakurai A.
    Gan To Kagaku Ryoho; 1984 Jul 15; 11(7):1387-93. PubMed ID: 6742865
    [Abstract] [Full Text] [Related]

  • 14. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
    McIntosh JK, Mulé JJ, Krosnick JA, Rosenberg SA.
    Cancer Res; 1989 Mar 15; 49(6):1408-14. PubMed ID: 2784349
    [Abstract] [Full Text] [Related]

  • 15. Tumoricidal activity of lymphotoxin (tumor necrosis factor beta) in vivo: its effects on macrophages.
    Higuchi M, Mitsuno T, Sugimoto M, Okamoto A, Hirose S, Tsukita S, Osawa T.
    J Biol Response Mod; 1988 Dec 15; 7(6):619-30. PubMed ID: 3265149
    [Abstract] [Full Text] [Related]

  • 16. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats.
    Debs RJ, Fuchs HJ, Philip R, Brunette EN, Düzgüneş N, Shellito JE, Liggitt D, Patton JR.
    Cancer Res; 1990 Jan 15; 50(2):375-80. PubMed ID: 2295077
    [Abstract] [Full Text] [Related]

  • 17. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
    McIntosh JK, Mulé JJ, Merino MJ, Rosenberg SA.
    Cancer Res; 1988 Jul 15; 48(14):4011-7. PubMed ID: 3260130
    [Abstract] [Full Text] [Related]

  • 18. Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorus-31 nuclear magnetic resonance study.
    Shine N, Palladino MA, Patton JS, Deisseroth A, Karczmar GS, Matson GB, Weiner MW.
    Cancer Res; 1989 Apr 15; 49(8):2123-7. PubMed ID: 2702653
    [Abstract] [Full Text] [Related]

  • 19. [Damaging action of human recombinant TNF on tumor vessels as an aspect of its anti-neoplastic action against Meth A sarcoma in mice].
    Nakamura H, Motoyoshi S, Seto Y, Kadokawa T, Nakata K, Iida M, Taguchi T.
    Gan To Kagaku Ryoho; 1987 Jan 15; 14(1):91-9. PubMed ID: 3800409
    [Abstract] [Full Text] [Related]

  • 20. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons.
    Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W.
    Cancer Res; 1986 Aug 15; 46(8):3990-3. PubMed ID: 2425938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.